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Objective: Alcohol addiction too often remains insufﬁciently treated. It shows the same
proﬁle as severe chronic diseases, but no comparable, effective basic treatment has been
established up to now. Especially patients with repeated relapses, despite all therapeutic
approaches, and patients who are not able to attain an essential abstinence to alcohol,
need a basic medication. It seems necessary to acknowledge that parts of them need
any agonistic substance, for years, possibly lifelong. For >14 years, we have prescribed
such substances with own addictive character for these patients. Methods: We present
a documented best possible practice, no designed study. Since 1997, we prescribed Dihy-
drocodeine (DHC) to 102 heavily alcohol addicted patients, later, also Buprenorphine,
Clomethiazole (>6weeks), Baclofen, and in one case Amphetamine, each on individual
indication. This paper focuses on the data with DHC, especially. The Clomethiazole-data
has been submitted to a German journal. The number of treatments with the other sub-
stances is still low. Results:The 102 patients with the DHC treatment had 1367 medically
assisted detoxiﬁcations and specialized therapies before! The 4 years-retention rate was
26.4%, including 2.8% successfully terminated treatments. In our 12-steps scale on clini-
cal impression, we noticed a signiﬁcant improvement from mean 3.7 to 8.4 after 2 years.
The demand for medically assisted detoxiﬁcations in the 2 years remaining patients was
reduced by 65.5%. Mean GGT improved from 206.6U/l at baseline to 66.8U/l after 2 years.
Experiences with the other substances are similar but different in details. Conclusion:
Similar to the Italian studies with GHB and Baclofen, we present a new approach, not
only with new substances, but also with a new setting and much more trusting attitude.
We observe a huge improvement, reaching an almost optimal, stable, long term status in
around 1/4 of the patients already. Many further optimizations are possible.
Keywords: dihydrocodeine, alcohol addiction
INTRODUCTION
We have been documenting the long term proﬁle of addiction dis-
eases in charts for>20 years. These charts show the severe chronic
character of the disease and the limited effect of most active mea-
sures against it in a terrifying manner. Nearly all patients have
undergone endless attempts to ﬁnally reach a stable abstinence,
and most of them ruined themselves in the process. The estab-
lished way of treatment and possible abstinence as the goal seem
to be insufﬁcient or wrong.
If a chronic or polyleptic disease like asthma, hypertension,
diabetes, rheumatic disease, and migraine is associated with too
many or heavy exacerbations, several sufﬁcient basic treatments
have been developed. Not so for alcohol dependence! The need is
extremely evident,mainly for patients with no working abstinence
and repeated relapses despite all therapeutic approaches and for
patients who are not able to reach an urgently needed abstinence
of alcohol.
Four main problems are most disturbing from alcohol depen-
dence: The somatic harm, the impossibility to control it sufﬁ-
ciently, the psychological alteration and, like in many addiction
diseases, the trust destroying underhandedness. If these distur-
bances are resolved, even a life with the long term need of a
type of medication is acceptable. The relevant goal is that these
disturbances disappear. Many people and even experts believe that
abstinence is a prerequisite for this – a clear confusion of condi-
tions and goal, especially, if abstinence does not work in the long
term, as shown in most of our charts.
Basic medication must help to reduce craving, relapses, and the
mentioned alcohol related problems. The ﬁrst hope was to achieve
this, using substances without any potential addiction inducing
capacity. The practical relevance and the prescription volume of
such substances, Acamprosate [reaching not 1% of the addicted
patients (Fritze, 2003; Lohse et al., 2008) or not 5%of the appropri-
ate patients (Fritze, 2007)],Naltrexone, andDisulﬁrame, remained
similarly limited like Naltrexone for opiate addicts.
The failure of the addiction avoiding substances is a hint for the
treatment. Addictive substances are used for tranquillization, to
blank out bad things in the brain, sometimes to overcomedispleas-
ing self-consciousness, as patients say. The displeasing, inhibiting
perceptions are sometimes described as a grave handicap, often
hard, or impossible to bear. Craving is repeatedly stronger than
willpower.
Many patients need an agonistic substance giving them some
of the positive effects of alcohol. Alcohol itself is too toxic
and connected with the described problems. Some substances,
e.g., Benzodiazepines and Cannabinoides, seem not to be well
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applicable in the long term,because of their negative impact on the
psychological resilience and of partly severe personality changes.
First encouraging results with Gamma-hydroxybutyrate
(GHB), a GABA (B) receptor agonist, are mainly documented
in Italian studies (Addolorato et al., 1996, 1998, 2000; Poldrugo
and Addolorato, 1999; Maremmani et al., 2001; Caputo et al.,
2003, 2005; Nava et al., 2006; Maremmani and Pacini, 2007). GHB
is effective in reducing alcohol intake and in maintaining absti-
nence. Dangerous and fatal poisonings with GHB were reported,
for instance from Spain (Galicia et al., 2008) and Sweden (Knud-
sen et al., 2008), and the substance is associated with a discussion
about its abuse as k.o.drops or rape drug (Andresen et al., 2010;
Németh et al., 2010). This seems to be a question of the right
organization of the whole treatment.
Baclofen with a similar agonism, but different effect in prac-
tice, became popular because of a successful self-experiment of
the physician Ameisen (2009). Once more Italians demonstrated
that it can be effective treating severely alcohol dependent patients
(Addolorato et al., 2002, 2007).
Clomethiazole is mainly prescribed as standard withdrawal
medication (e.g., Hillemacher et al., 2008). Its use as agonistic
substance for long term treatment, almost without therapeutic
concept, was connected with life threatening emergency events,
because of combined Alcohol–Clomethiazole poisonings. Ofﬁ-
cial declarations deﬁned Clomethiazole as obsolete for outpatient
treatment (Deutsches Ärzteblatt, 1997).
Some alcohol dependents report good effects of ampheta-
mines, concerning alcohol. A therapeutic use is not proven in this
indication.
What about the Opioides? Heroin addicts frequently report
that they stopped drinking, when they switched to heroin. A
connection between alcohol and opiate receptors has been sci-
entiﬁcally known for many years (Gianoulakis, 1993; Froehlich
and Li, 1994; Gianoulakis and de Waele, 1994; Gianoulakis et al.,
1996). The partial efﬁcacy of opiate antagonists (Volpicelli et al.,
1995) also demonstrates this connection. Caputo et al. (2002)
again Italians, published possible effects of short-term methadone
administration in reducing alcohol consumption in a popula-
tion of non-alcoholic heroin-addicted patients. On the other side,
manymethadonemaintenance patients have severe alcohol related
problems. In individual cases raising the dosage of the opioid
to very high dosages (methadone for instance to 400mg daily)
was successful, giving us another hint that opioides can help to
overcome alcohol addiction (Ulmer, 2010).
Two pioneering German doctors published ﬁrst convinc-
ing experiences, treating alcohol dependent patients with DHC
(Grimm, 1992; Elias, 1996). This idea was already published in
1929 (Kafemann, 1929), but then forgotten for decades.We started
to carefully prescribe DHC in 1997, when one desperate patient,
permanently suffering fromcraving and relapses, reported a strong
reduction of his craving after the intake of analgetic tablets with
each 30mg Codeine TID (Ulmer, 2002; Ulmer et al., 2009).
MATERIALS AND METHODS
Meanwhile, we have treated 102 (M/F: 71/31) heavily alcohol
addicted patients with DHC. In seven patients, who had prob-
lems with side effects of DHC or the necessary discipline (intake
QID), we have alternatively tried Buprenorphine. Clomethiazole
was evaluated as long term prescription, if we prescribed it for
>6weeks, in 40 patients. Our experience with Baclofen is ini-
tially based on seven patients, and in one patient, we have the best
results, prescribing amphetamines. Our data is not the result of a
study. No single prescription was study-motivated. Each patient
signed an informed consent to be treated on a not established and
therefore possibly dangerous way, including a very special respon-
sibility. The treatment was always prescribed with the intention
to provide the best possible treatment. But we always accompany
our treatments with systematic documentation. This enables us to
report what we observe.
RESULTS
The medical history alone of the 102 DHC-treated patients com-
prehended 1184 medically assisted detoxiﬁcations, 918 of them in
a hospital, and 183 therapies in specialized clinics. Mean age of the
patientswas 46.6 years,meandurationof ostentatious alcohol con-
sumption 23.2 years. The indication was an inability to live with or
without alcohol in 87.3%, in 27.5% urgent somatic, and in 13.7%
urgent social reasons. Nineteen patients had a history of sporadic
or dependent use of opiates, overcome for 9.2 years on average.
The history of the patients treated with other substances than
DHC is comparable. Clomethiazole was prescribed additionally
to DHC, Buprenorphine, Methadone, or Baclofen in most cases.
It was prescribed as single main drug for only 13 patients.
The patient whom we are treating with amphetamines, had
a long stable history of >30 years with Fenetyllin prescribed by
another physician, until it was suddenly withdrawn from the
market. He tried to compensate with alcohol but 10 beers daily
destroyed his life within only 3 years. Antidepressants, psychother-
apy, and a treatment in a specialized hospital did not help. DHC
from us was successful against alcohol, but not against a “black
hole” in his soul. He has been much better treated with additional
Amphetamin sulfate since 10/09, the present dosage is 18mg/day
(10.8mg Amphetamine).
DHC normally has to be taken QID. Starting dosage in most
cases was 120mg (4× 30mg) daily. The mean dosage was raised
up to 336mg after 57months and then slowly reduced, to 137mg
after 100months (DHC-base). We have tended toward slightly
higher dosages (Figure 1) in the last years. Of 72 patients, included
until 08/07, 17 (23.6%) remained on treatment 4 years later. Two
had successfully ﬁnished the treatment without further relapses
(4 years-retention rate together 26.4%; Figure 2). This rate is
32.2%, if all 13, who ﬁnished the treatment within the ﬁrst month,
were excluded. Forty-eight percent of all patients remained in our
treatment, after 4 years, even if DHC treatment was discontinued.
In our 12-steps scale on clinical impression, we noticed a statisti-
cally signiﬁcant improvement from mean 3.7 to 8.4 after 2 years
(n = 29).
We have data about medically assisted detoxiﬁcations during
the last 2 and the ﬁrst 2 years on DHC from 19 of them: The num-
ber was reduced by 65.5% from 58 before to 20 during the ﬁrst
2 years after DHC start (Figure 3). Mean GGT improved from
206.6 to 66.8U/l after 2 years (p = 0.009; Figure 4). The MCV
value also showed an improvement from 94.4 ﬂ at baseline to 92.9
ﬂ after 2 years (Figure 5).
Mean GGT of patients with additional chronic hepatitis C
(n = 12) improved from 260.8U/l at baseline to 160.3U/l after
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FIGURE 1 | Average daily dosage DHC. It was possible to control and to reduce the dosage over years. In some patients, the reduction was postponed in favor
of the optimal dosage for a sustained stabilization, after a few years (peak of the dosage at the right).
FIGURE 2 | Patients, remaining in our treatment, with or without DHC, including patients, who had regularly finished the DHC treatment without
further relapse – insertion until 2007.
1 year (p = 0.139), 128.3 after 2 years (p = 0.122), and 116.8 after
4 years (n here only 3).
Clomethiazole was prescribed more as an interim-medication
and became a long term basic medication only in three patients.
In most of the other cases, where it was prescribed alone, it was
terminated early because of relapses, lost of follow up, or planned
detoxiﬁcation.
DISCUSSION
We do not present a designed study but the documentation of best
possible practice. This means scientiﬁc limitations, no prospec-
tive design, external control, ethics committee, and no ﬁnancial
support for better statistics or evaluations. The scale of clini-
cal impressions is not yet validated scientiﬁcally. On the other
hand: We were not dependent on ﬁnancial sponsors and could
do much more than in studies, we could offer the best appraised
treatment. It had the character of normal daily practice. Thus, we
can address more practical aspects. These are as essential as the
scientiﬁc aspects.
We are always aware that providing new, quasi experimental
treatments can be dangerous for patients as well as for the doc-
tor. Therefore, we permanently set high value on our integration
in quality circles, interdisciplinary cooperation, and professional
associations. We try to be especially accurate and to document as
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FIGURE 3 | Medically assisted detoxifications – patients with documented 2years before and after start of the DHC treatment (58–20=−65.5%!).
FIGURE 4 | GGT values with 95% confidence intervals during the last year before and the first 2 years on DHC treatment.
systematically as possible. This is generally a condition for bet-
ter addiction medicine. We operate only on the basis of already
existing knowledge and experience, never blindly experimenting.
In most of our cases, not to leave the usual standard, would also
have been dangerous, sometimes for the life of the patients. We
always followed a reasonable probability to improve the situation
with the new approach.
The immense number of previous detoxiﬁcations and ther-
apies indicates the desperate state of many patients. Less than
10% of our charts, for >20 years, contain a documentation of a
successful escape, with or without medication. Normally, it is a
severe chronic disease with repeated exacerbations. Medical spe-
cialists and perspectives of a sufﬁcient treatment aremissing,when
patients are discharged after countless detoxiﬁcations. Missing
concepts induce permanently failing attempts to escape the addic-
tion, expensive, dangerous, undermining their self-conﬁdence.
Result is again and again alcohol, the most adverse substance
for a life with an addiction disease. The patients must live with
this disease, but they have no adequate perspective, like with the
most other chronic illnesses. To commit the patients as medical
specialist is a very new perspective. Our 4 years-retention rate of
together 48% in such desperate patients, 26.4% on DHC, indicates
Frontiers in Psychiatry | Addictive Disorders March 2012 | Volume 3 | Article 21 | 4
Ulmer et al. Dihydrocodeine/agonists for alcohol dependents
FIGURE 5 | MCV values with 95% confidence intervals during the last year before and the first 2 years on DHC treatment.
a new approach. We get closer to the treatment standard in other
chronic diseases.
This is only possible with an effective basicmedication.Accord-
ing to the nature of the disease and our experience, it must often
be an agonistic substance or a combination of substances giving
the patients at least a part of the alcohol effects. They are addicted,
because they need something, like a patient with a thyroid hypo-
function. The general – of course questionable – success of the
maintenance therapies for opiate addicts, standard for a long ago,
indicates the same. Concerning alcohol addiction, several studies
are needed, to ﬁnd out the best substances, combinations, and the
best setting, generally and individually. The established mainte-
nance treatment for opiate addicts suffers widely of some easily
avoidable management failures and often also of questionable
attitudes.
Therefore, not alone the use of agonistic substances has to be
discussed but also the right management in combination with our
attitudes. It is not sufﬁcient only to provide with good substances
like a provisioning of mass, even if an additional psychosocial care
is organized.
The fear, to add a further and possibly more severe addic-
tion to an existing addiction is coherent, but without reason.
We enable a crucially better life with the addiction in the four
essential parameters: somatic health, control, psychological sta-
bility, and underhandedness. In case of an insufﬁcient effect and
new relapses with alcohol, we can leave the treatment tapering the
dosage, try another substance, possibly in combination, or con-
tinue, possibly increasing the dosage, because it appeared as the
right way. All options are easily possible in most of such cases, of
course connected with all psychological approaches.
In case of success, it is usually best to leave the patients on the
medication for years, because, according to the chronic character
of the disease, the risk of a change for the worse is higher the earlier
we ﬁnish the treatment.
Prescribable agonistic substances are much better than alcohol.
Almost no long term toxicity of opioides and the other substances
is known. The experiences with the controllability are nearly per-
fect. If we advise them to take 30mg QID, they document an
absolute correct use: 30mg QID. Also concerning the mental and
intellectual capacity, our substances handicap and change the per-
son less than alcohol. The situation of most patients has improved
crucially.
Most of our prescribable substances are more dangerous, partly
life threateningonly in case of acute abuse andmixed intoxications.
This is especially documented for GHB (Galicia et al., 2008; Knud-
sen et al., 2008), Clomethiazole (Deutsches Ärzteblatt, 1997), and
DHC(Penning et al., 1993). The reaction of the experts aswell as of
the public authorities is always preferably too cautious. The good
Italian experiences with GHB (Addolorato et al., 1996, 1998, 2000;
Poldrugo and Addolorato, 1999; Maremmani et al., 2001; Caputo
et al., 2003, 2005; Nava et al., 2006; Maremmani and Pacini, 2007)
should have been internationally proven and integrated into ther-
apy for a long time. But the substance is nearly not available in
most countries.
Clomethiazole has lost its license for outpatient treatment in
Germany and is not available in several countries. Most experts
believe that its outpatient use is obsolete. The use of DHC for opi-
ate addicts is, despite published good data (Ulmer, 1997; Krausz
et al., 1998; Robertson et al., 2006), similarly restricted in Ger-
many, and has been reduced from ca. 80 to 0.3% (Bundesinstitut
für Arzneimittel und Medizinprodukte, 2011).
The professional world and public authorities are mistrusting.
In doubt, they keep the doors of any potential development closed.
But this is dramatic for the dependents. The observed tremen-
dous difference between a normal treatment offer and the offer
including exactly these medications remains withheld from them.
There will be no good development without bridging the
gap between the two experiences: Dangerous abuse and a well
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controlled, very beneﬁcial therapy on the other side. To win the
conﬁdence of the professional world and public authorities needs
convincing solutions minimizing the danger of abuse as well as
scientiﬁc results.
Putting the new treatment under cautious restrictions with a
lot of control is the absolute wrong way. It undermines the trust
between society and the physicians who provide this therapy, and
also between the therapeutic team and the patient. Controls are
necessary, of course, but if they get a central importance, con-
nected with restrictions, we are on the old trip: taking care for
the right way and mistrusting that the involved ones are aim-
ing in the same direction. Restrictions, for instance demanding
a special license for physicians and interfering in the choice and
dosages of medical substances, are potentially as dangerous for
the whole development as too much liberty. Permanently mis-
trusting controls, centralization in too few centers, questionable
regulations and an attitude which always tries to ﬁrst serve safety
and only in second line patients and professionals, are often
violating basics of good treatment and fundamental needs and
rights of the patients, who have to take the basic medication for
many years, sometimes lifelong. Long term patients need, more
than others, trust as a central attribute of the treatment. It is
absolutely essential to avoid or to overcome a second class iden-
tity. A good treatment construction must help the patients to have
no further reason for underhandedness. This is only possible if
restrictions are not the regular reaction to missing success or other
problems.
The investigation of a therapy which possibly can be abused
must essentially be connected with a comprehensive development
of a setting which guarantees a high grade of conﬁdence. The
therapy needs to be controlled, but trustfully. Trust is only pos-
sible if all involved people are convinced that everyone is really
aiming for the best. And trust is always mutual.
This is not difﬁcult, but we need a new organization of the
whole treatment:
– implementing as many physicians as possible, avoiding concen-
tration of patients,
– ensuring quality assisting training, specialization, reﬂexion,
– supporting quality circles, interdisciplinary cooperation, sup-
port centers, and a regular evaluation of the satisfaction
of all,
– deﬁning standards like
o good anamnesis,
o normal checks,
o regular qualiﬁed talks,
o written information about the concept, the medication, the
dosage,
o clear advise, how to take the medication, and prescribing not
much more than needed until the next appointment,
Intelligent management can prevent wrong usage and ensure
a sufﬁcient quality without exorbitant bureaucracy, constraining
regulations, and dramatic disadvantages for the patients – an
essential basis for the development of trust on all levels.
In the treatment of Alcohol addiction, our experience com-
prises different substances. Our way to the use of these sub-
stances is an example for an alternative medical advancement
in practice: Following the hints of the patients, as in our ﬁrst
DHC- and Amphetamine-patients, trying all possible standard
treatments, cooperating with as many other experts as possible,
and connecting all these aspects with the experience as inte-
grated specialized physicians. New approaches are then, very care-
fully and systematically, possible much earlier than controlled
studies, which are sometimes never realized, sometimes many
years later.
Our main experience is based on DHC, altogether our best sub-
stance, up to now. Many patients fear a medically induced opiate
addiction, fewhave intolerable, but innocuous side effects like pru-
ritus, nausea, or constipation, few have no positive effect and few
do not like the mental effect, but if this all is not the case, the effect
on the general feeling and the craving is often broadly ideal. In very
few patients, we have tried Buprenorphine, in case of problems
with DHC. The report of these few patients was: General feeling
o.k., but less reduction of the Alcohol craving, possibly a ques-
tion of the right dosage, which is limited in our setting, because
of the costs. The effect of a constant low dosage Clomethiazole is
mainly a slight sedation, much less inﬂuence on the general feel-
ing as with DHC. The reports concerning the reduction of the
craving are different. To avoid mixed intoxications with alcohol,
the outpatient dosage must be strictly limited and patients need
good instruction and supervision. Our experience with Baclofen
is still too small for a relevant impression. The dosage in Italian
trials was 30mg (Addolorato et al., 2007), and Italian colleagues
say: The effect of Baclofen would be less impressive than of GHB.
Our ﬁrst impression was similar. With higher dosages, >100mg,
the patients feel a clear reduction of strain and anxiety. The effect
on the general feeling is not as comprehensive and the reduction
of the alcohol craving seems less than under DHC. An advantage,
similar to GHB, might be the less severe addiction, compared to
opioides and Clomethiazole.
These are only preliminary impressions. Scientiﬁc comparisons
and the evaluation of combinations should be part of ofﬁcial trials.
The obvious effect of different substances out of different classes
indicates hope on the development of a very individual medical
offer in the future, like in other chronic diseases (e.g., depression).
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